CD19 and acute lymphoblastic leukemia: It is most often seen in patients who harbor mixed lineage leukemia (MLL) rearrangements, such as infants with B-ALL, when the leukemic phenotype changes from lymphoid to myeloid in response to CD19-directed immunotherapy.